STOCK TITAN

Neogenomics Inc. - NEO STOCK NEWS

Welcome to our dedicated news page for Neogenomics (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neogenomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neogenomics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.32%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
Neogenomics Inc.

NASDAQ:NEO

NEO Rankings

NEO Stock Data

1.80B
125.95M
1.18%
101.05%
5.67%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
Fort Myers

About NEO

neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig